Labcorp Holdings (LH) could be a solid choice for investors given its recent upgrade to a Zacks Rank #2 (Buy). This upgrade primarily reflects an upward trend in earnings estimates, which is one of ...

Labcorp Holdings ( ($LH) ) has issued an announcement. On October 8, 2025, Labcorp Holdings Inc. announced that its Board of Directors declared a ...

Short interest is the number of shares that have been sold short but have not yet been covered or closed out. Short selling ...

Labcorp Holdings is set to release its third-quarter earnings this month, and analysts anticipate solid double-digit growth ...

Brings decades of leadership in laboratory testing, clinical diagnostics, payor strategy, and sales growth Extensive track record in ...

On Tuesday, the College of Healthcare Information Management Executives (CHIME) held an event to launcha $1 millionglobal ...

The Monongalia County Health Department offers affordable sexual health resources, free STI testing, partner notification and ...

Evercore ISI raised the firm’s price target on Labcorp (LH) to $305 from $300 and keeps an Outperform rating on the shares.

Burlington-based Labcorp has launched the first blood-based test cleared by the U.S. Food and Drug Administration (FDA) for aiding in the diagnosis of Alzheimer's disease.

In the assessment of 12-month price targets, analysts unveil insights for Labcorp Hldgs, presenting an average target of $297.5, a high estimate of $310.00, and a low estimate of $282.00. This current ...

Labcorp is seeking tax abatements from Greenfield City Council for improvements to its campus on U.S. 40, including ...

Labcorp, a provider of laboratory services, has partnered with Roche to implement Roche’s FDA-cleared VENTANA DP 600 and DP ...